View text source at Wikipedia

Razpipadon

Razpipadon
Clinical data
Other namesCVL-871; PF-06669571; PW-0464
Routes of
administration		Oral administration
Drug classDopamine receptor agonist
Identifiers
  • 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H17F2N3O4
Molar mass389.359 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C
  • InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26)
  • Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2][3][4] It is taken via oral administration.[1]

Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][5] The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects.[6][7]

The drug was originated by Pfizer and is under development by Cerevel Therapeutics.[1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e "CVL 871 - AdisInsight".
  2. ^ a b Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
  3. ^ Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL (June 2024). "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. doi:10.1080/14728214.2024.2363215. PMID 38822731.
  4. ^ Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP (July 2023). "An Update on Apathy in Alzheimer's Disease". Geriatrics (Basel). 8 (4): 75. doi:10.3390/geriatrics8040075. PMC 10366907. PMID 37489323.
  5. ^ "CVL-871 - Cerevel Therapeutics". 2 January 2020.
  6. ^ Webber HE, Lopez-Gamundi P, Stamatovich SN, de Wit H, Wardle MC (January 2021). "Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults". Neurosci Biobehav Rev. 120: 123–158. doi:10.1016/j.neubiorev.2020.11.004. PMC 7855845. PMID 33202256. Similarly, augmenting DA using a D1 agonist (PF-06412562; 6mg, 15mg, 30mg) increased willingness to exert physical effort for reward (Soutschek et al., 2020).
  7. ^ Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN (April 2020). "Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences". Biol Psychiatry. 87 (7): 678–685. doi:10.1016/j.biopsych.2019.09.002. PMID 31668477.
[edit]



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.